AzTrials
AzTrials

Metastatic Prostate CancerPhase 1NCT05617885

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

A Phase 1 study testing Darolutamide, Abemaciclib and GNRH-A Leuprolide Acetate in people with Metastatic Prostate Cancer and Non-metastatic Prostate Cancer, run by Praful Ravi, MB BCHir, MRCP at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and advanced prostate cancers. Read more about this study

Who is it for?
Ages 18 years and older, men only
What is being tested?
Darolutamide, Abemaciclib and GNRH-A Leuprolide Acetate
Could I receive a placebo?
No, everyone receives an active treatment
How many people
9 participants
Where
1 siteUnited States
Study dates
9 Aug 2023to 1 Jun 2026
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Provision of signed informed consent prior to any study specific procedures, or have a legally authorized representative sign on the participant's behalf.
  • Ability to swallow oral medications and comply with study procedures and requirements.
  • Males ≥18 years
  • Histologically or cytologically confirmed adenocarcinoma of the prostate without histologic variants (including neuroendocrine differentiation, small cell, sarcomatoid, ductal adenocarcinoma, squamous or transitional cell carcinoma) comprising >50% of the sample as determined by academic medical center pathology review; men without histologic confirmation are eligible provided there is unequivocal evidence of prostate cancer (eg. very high PSA) in the view of the treating physician.
  • M0 or M1 (by CT/MRI and bone scans) CRPC with evidence of progression at study entry demonstrated during continuous androgen deprivation therapy (LHRH/GnRH agonists/antagonists/post orchiectomy) and castrate level of serum testosterone (≤50 ng/dl). Progression is defined as one or more of the following:
  • Sequence of at least 2 rising PSA values at a minimum of 1-week intervals with the last result being at least 1.0 ng/mL if confirmed PSA rise is the only indication of progression. Patients who received an anti-androgen (flutamide, bicalutamide or nilutamide) must have PSA progression ≥4 weeks after the last dose.
Show all 50Show fewer
  • Radiographic progression per RECIST 1.1 for soft tissue and/or per PCWG3 for bone (i.e., appearance of ≥2 new bone lesions), with or without PSA progression.
  • Serum testosterone level must be ≤50 ng/dL (1.73 nmol/L) at the screening visit. Participants who have not undergone bilateral orchiectomy are required to continue LHRH/GnRH agonists/antagonists) throughout the study.
  • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).
  • Participants must have adequate organ and marrow function as below:
  • System Laboratory Value
  • Hematologic
  • ANC ≥1.5×109/L
  • Platelets ≥100×109/L
  • Hemoglobin ≥9g/dL (≥90g/L) independent of transfusions
  • Hepatic
  • Total Bilirubin ≤1.5 × ULN OR <2 × ULN if known or suspected Gilbert's syndrome
  • ALT and AST ≤3 × ULN OR ≤5 × ULN if liver metastases present
  • Renal
  • eGFR ≥30 mL/min/1.73 m2 (based on Cockcroft-Gault formula [Appendix D] OR 24 hour urine collection.
  • Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; ANC = absolute neutrophil count; eGFR = estimated glomerular filtration rate; ULN = upper limit of normal.
  • The effects of darolutamide and abemaciclib on the developing human fetus are unknown. Participants and their partners must agree to use an effective contraception method (hormonal or barrier method of birth control, or abstinence) during the study and for 3 weeks after the last dose of study treatment (darolutamide and/or abemaciclib) if engaged in sex with a woman of childbearing potential, and participants must not donate sperm during this period. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately.
  • Provision of signed informed consent prior to any study specific procedures, or have a legally authorized representative sign on the participant's behalf.
  • Ability to swallow oral medications and comply with study procedures and requirements.
  • Males ≥18 years.
  • Histologically confirmed adenocarcinoma of the prostate without histologic variants (including neuroendocrine differentiation, small cell, sarcomatoid, ductal adenocarcinoma, squamous or transitional cell carcinoma) comprising >50% of the sample as determined by academic medical center pathology review.
  • ≥3 biopsy cores (either systematic or targeted, or a combination) involved with prostate cancer. Prostate biopsy must have been performed within 6 months of screening. <3 biopsy cores with cancer are allowed if the patient has >1cm of tumor or ≥cT3 disease on MRI prostate.
  • Participants must have at least 1 biopsy core with either:
  • Gleason ≥8 OR
  • Gleason 4+3=7 AND at least one of the following:
  • PSA >20ng/dL
  • ≥cT3 disease by MRI
  • Evidence of EPE on biopsy
  • No evidence of metastatic disease as determined by radionuclide bone scan and CT/MRI, and/or PSMA-PET. Pelvic lymph nodes <2cm in short axis are permitted. If PSMA-PET does not show evidence of metastatic disease, CT/MRI and bone scan is not required.
  • Either PSMA-PET or CT/MRI abdomen and bone scan is required before C1D1. NOTE: participants with possible evidence of bone, nodal or visceral metastatic disease on PSMA-PET imaging at baseline (but not CT/MRI or bone scan) are eligible and their participation is encouraged. All participants treated at DFCI must undergo PSMA-PET at baseline or within 28 days of C1D1 (per institutional practice) and will also undergo a research-only PSMA-PET after completion of therapy and prior to RP.
  • Participants must be candidates for RP and be considered surgically resectable by a Urologist.
  • ECOG performance status ≤1 (Karnofsky ≥70%, see Appendix A).
  • Participants must have adequate organ and marrow function as defined below:
  • System Laboratory Value
  • Hematologic
  • ANC ≥1.5×109/L
  • Platelets ≥100×109/L
  • Hemoglobin≥9g/dL (≥90g/L) independent of transfusions
  • Hepatic
  • Total Bilirubin ≤1.5 × ULN, <2 × ULN if known or suspected Gilbert's syndrome
  • ALT and AST ≤3 × ULN
  • Renal
  • eGFR ≥30 mL/min/1.73 m2 (based on Cockcroft-Gault formula [Appendix D] OR 24 hour urine collection.
  • Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; ANC = absolute neutrophil count; eGFR = estimated glomerular filtration rate; ULN = upper limit of normal.
  • The effects of darolutamide and abemaciclib on the developing human fetus are unknown. Participants and their partners must agree to use an effective contraception method (hormonal or barrier method of birth control, or abstinence) during the study and for 3 weeks after the last dose of study treatment (darolutamide and/or abemaciclib) if engaged in sex with a woman of childbearing potential, and participants must not donate sperm during this period. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately.

Who cannot join

  • Participants who have had chemotherapy or radiotherapy within 4 weeks prior to planned cycle 1 day 1 of study treatment.
  • Participants who have received anti-neoplastic intervention or experimental antineoplastic therapy within 14 days of planned cycle 1 day 1 of study therapy.
  • Participants who are receiving any other investigational agents.
  • Participants who have previously received darolutamide, abemaciclib or another CDK4/6 inhibitor.
  • Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e. have residual toxicities ≥Grade 2) with the exception of alopecia.
  • Any of the following within 6 months before planned cycle 1 day 1 of study therapy:
Show all 35Show fewer
  • Stroke
  • Myocardial infarction
  • Severe/unstable angina pectoris
  • Coronary/peripheral artery bypass graft
  • Congestive heart failure New York Heart Association (NYHA) Class III or IV.
  • Known or suspected contraindications, hypersensitivity or allergy to darolutamide or abemaciclib or to any of their excipients.
  • Participants with hepatitis C, hepatitis B or human immunodeficiency (HIV) who are on anti-viral therapy that has the potential to interact with darolutamide or abemaciclib.
  • Participants with untreated brain metastases. Participants with treated brain metastases are eligible if follow-up brain imaging at least 4 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression and ongoing corticosteroids are not required. Participants with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.
  • Participants treated with drugs known to be strong inhibitors and/or inducers of cytochrome P450 3A4 (CYP3A4) and the treatment cannot be discontinued or switched to a different medication at least 5 half-lives prior to starting study drug.
  • NOTE: precaution is warranted with concomitant use of agents with a narrow therapeutic index that are substrates of P-gp, BCRP and OCT1.
  • Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
  • The participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • Concurrent active malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of the investigational regimen. Patients with non-melanomatous skin cancer, superficial bladder cancer, cancer not needing active therapy for at least 2 years, cancer for which the treating investigator deems the subject to be in remission, or any prior malignancy that was treated with curative intent (no evidence of disease for at least 3 years) are permitted to enroll.
  • 3.4.1 Prior radiotherapy, bilateral orchiectomy, investigational therapy or systemic therapy (including LHRH/GnRH agonists/antagonists, anti-androgens, CYP17 inhibitors, AR antagonists) for prostate cancer. LHRH/GnRH agonists/antagonists are permitted if begun within 4 weeks of day 1; up to 4 weeks of bicalutamide is permitted if it is stopped 2 weeks prior to day 1. Prior therapy with 5-⍺-reductase inhibitors is allowed but must be stopped 2 weeks prior to day 1.
  • Hypogonadism or severe androgen deficiency as defined by screening serum testosterone < 200ng/dL. Patients who have a low screening testosterone due to prior ADT (per 3.4.1) will still be allowed to enroll on study if they do not have a known history of hypogonadism or severe androgen deficiency.
  • Major surgery or radiotherapy within 4 weeks of start of treatment.
  • Any of the following within 6 months before randomization:
  • Stroke
  • Myocardial infarction
  • Severe/unstable angina pectoris
  • Coronary/peripheral artery bypass graft
  • Congestive heart failure New York Heart Association (NYHA) Class III or IV.
  • Known or suspected contraindications, hypersensitivity or allergy to darolutamide or abemaciclib or to any of their excipients.
  • Participants with hepatitis C, hepatitis B or human immunodeficiency (HIV) who are on anti-viral therapy that has the potential to interact with darolutamide or abemaciclib.
  • Patient treated with drugs known to be moderate or strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) and the treatment cannot be discontinued or switched to a different medication at least 5 half-lives prior to starting study drug.
  • NOTE: precaution is warranted with concomitant use of agents with a narrow therapeutic index that are substrates of CYP3A4, P-gp, BCRP and OCT1.
  • Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
  • The participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min] or history of renal transplant, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • Concurrent active malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of the investigational regimen. Patients with non-melanomatous skin cancer, superficial bladder cancer, cancer not needing active therapy for at least 2 years, cancer for which the treating investigator deems the subject to be in remission, or any prior malignancy that was treated with curative intent (no evidence of disease for at least 3 years) are permitted to enroll.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215

Other trials in United States

About this study

Official title: A Phase 1/2 Study of Darolutamide and Abemaciclib in High-Risk Prostate Cancer

This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and advanced prostate cancers. The first phase of the study is to establish a recommended dose for the second phase.

The names of the study drugs and interventions involved in this study are:

Read more
  • Darolutamide
  • Abemaciclib
  • Androgen deprivation therapy (ADT) - this includes several different treatments, including Gonadotropin-Releasing Hormone (GnRH) antagonists and agonists

It is expected that about 93 people will take part in the research study.

Treatment is expected to last 6 months with a follow up period of up to 4.5 years.

Read the detailed description

This research study is a Phase I/II clinical trial to determine the safety and efficacy of the combination of abemaciclib and darolutamide with androgen deprivation therapy (ADT) in the treatment of metastatic and non-metastatic castration-resistance prostate cancer (CRPC) and for participants with high-risk, localized prostate cancer who will be undergoing radical prostatectomy (RP). A Phase I/II clinical trial tests the safety of investigational drugs with a lead-in phase and attempts to define the maximum tolerated dose of the investigational drugs to use for the second phase. "Investigational" means that the drugs are being studied together for the first time.

The names of the study drugs and interventions involved in this study are:

  • Darolutamide
  • Abemaciclib
  • Androgen deprivation therapy (ADT) - this includes several different treatments, including Gonadotropin-Releasing Hormone (GnRH) agonists, Leuprolide and Goserelin, and GnRH antagonist, Degarelix

In Phase I, participants will receive abemaciclib in combination with darolutamide and ADT at different dosages.

In Phase II, participants will be randomized into two groups of treatment: abemaciclib, darolutamide, and ADT versus darolutamide and ADT. Randomization means that participants are placed into one of the treatment groups by chance, like flipping a coin.

The U.S Food and Drug Administration (FDA) has approved androgen deprivation therapy as a treatment for prostate cancer. The FDA has not approved abemaciclib for prostate cancer but it has been approved for other uses. Abemaciclib is approved for use in advanced breast cancer. The FDA has approved darolutamide as a treatment option in men with non-metastatic CRPC but it is not approved in men with metastatic CRPC or localized prostate cancer. Research procedures include screening for eligibility, study treatment including evaluations, blood collection, and radiology scans of the prostate.

It is expected about 93 participants will take part in this research study.

Treatment is expected to last 6 months with a follow up period of up to 4.5 years.

Lilly is supporting this research study by providing funding and the study drug, abemaciclib. Bayer is supporting the study by providing the study drug, darolutamide.

The trial was intended to be Phase 1/2 but did not move forward to Phase 2 since the company providing drug and funding (Lilly) withdrew support for the trial based on data relating to abemaciclib in advanced prostate cancer.

Being tested
Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate, GNRH-A Goserelin, Degarelix
Keywords
Prostate Cancer, Hormone Therapy, Androgen Deprivation Therapy, Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Radical Prostatectomy
Medical subject headings
Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DarolutamideDrug

    Also called Nubeqa

    Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.

  • AbemaciclibDrug

    Also called Verzenio

    Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a "CDK4/6 inhibitor". CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing.

  • GNRH-A Leuprolide AcetateDrug

    Also called Eligard, Lupron Depot, Lupron Depot-Ped

    Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.

  • GNRH-A GoserelinDrug

    Also called Zoladex

    Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.

  • DegarelixDrug

    Also called Firmagon

    Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.

Study groups in NCT05617885
Study groupRoleWhat they receive
Phase 1 Lead In in CRPCExperimentalStandard 3+3 dose escalation scheme with 3 dose levels of abemaciclib and a constant dose of darolutamide, per protocol, for 6, 28-day cycles
Receives: Drug: Darolutamide; Drug: Abemaciclib; Drug: GNRH-A Leuprolide Acetate; Drug: GNRH-A Goserelin; Drug: Degarelix
Phase 2 - Neoadjuvant Darolutamide and ADT prior to Radical ProstatectomyExperimentalper protocol, for 6, 28-day cycles
Receives: Drug: Darolutamide; Drug: GNRH-A Leuprolide Acetate; Drug: GNRH-A Goserelin; Drug: Degarelix
Phase 2 - Neoadjuvant Darolutamide, Ademaciclib, and ADT prior to Radical ProstatectomyExperimentalper protocol, for 6, 28-day cycles
Receives: Drug: Darolutamide; Drug: Abemaciclib; Drug: GNRH-A Leuprolide Acetate; Drug: GNRH-A Goserelin; Drug: Degarelix

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phase 1 - Number of Subjects With Dose Limiting Toxicity (DLT)

    Dose Limiting Toxicity (DLT) for Phase 1 will be defined as any abemaciclib or darolutamide-related toxicity resulting in discontinuation or dose reduction within the first 28 days of treatment, using NCI CTCAE criteria version 5.0.

    DLTs will be defined as any of the following events:

    • Any death
    • Dose delay of >14 days for the study drug(s) due to an adverse event
    • Non-hematologic toxicity:
    • Grade 3 or higher
    • Hy's Law cases (AST or ALT >3 x upper limit of normal (ULN) AND total bilirubin >2 x ULN AND ALP <2 x ULN AND no other reason for liver injury)
    • AST or ALT >8 x ULN or AST or ALT > 5 x ULN for ≥14 days regardless of the absence of presence of hepatic metastases
    • Hematologic toxicity:
    • Grade 4 that persists for more than 7 days
    • Grade 3 or higher thrombocytopenia with clinically significant bleeding
    • Febrile neutropenia

    Measured: Within the first 28 days of treatment (Cycle 1)

  2. Phase 1 - Maximum Tolerated Dose (MTD) of Abemaciclib

    The Maximum Tolerated Dose (MTD) for the study drug is defined as the maximum dose combination at which <33% of patients experience a Dose limiting toxicity (DLT) during Cycle 1 (the DLT-evaluation period). If a DLT is observed in 1 of 3 patients, then 3 additional patients will be enrolled at that same dose level. Dose escalation will continue to a dose of abemaciclib 200mg bid, which is the maximal dose levels. If DLTs are seen in 0-1 of 6 patients at dose level +1 (darolutamide 600mg bid and abemaciclib 200mg bid), then this will be the RP2D; otherwise the maximally tolerated dose (MTD) will be the RP2D.

    Measured: Within the first 28 days of treatment (Cycle 1)

  3. Phase 1 - Recommended Phase 2 Dose (RP2D) for Abemaciclib

    RP2D will be determined after a Maximum Tolerated Dose (MTD) is identified or the maximum planned dose is achieved. RP2D is defined as no more than 0-1 patients with dose limiting toxicity during cycle 1, out of 6 at maximal dose level. Otherwise, the maximally tolerated dose will be used.

    Measured: Within the first 28 days of treatment (Cycle 1)

  4. Phase 2 - Pathological Response Rate

    Pathologic response is defined as achieving either a complete response (pCR) or minimal residual disease (MRD, defined as ≤5mm residual tumor) at Radical Prostatectomy (RP) in both arms

    Measured: Disease evaluated from baseline to Pre-Radical Prostatectomy (RP), up to 6 months

Secondary outcomes (8)

  1. Phase 1 - Objective Response Rate (ORR)

    The objective response rate (ORR) is defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

    Measured: Disease evaluated every 12 weeks, up to 6 months

  2. Phase 1 - Radiographic Progression-Free Survival (rPFS) at 6 Months

    Radiographic Progression-Free Survival (rPFS) is defined as the time from protocol treatment initiation to the earlier of progression by PCWG3 criteria or death due to any cause. PCWG3 progression is defined as when it is felt by the treating physician that the patient is "no longer clinically benefiting" (NLCB) from therapy. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.

    rPFS at 6 months will be evaluated by the Kaplan Meier methodology.

    Measured: Evaluated every 12 weeks, up to 6 months

  3. Phase 1 - Grade 3 or Higher Treatment-Related Toxicity Rate

    Defined as all grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation.

    Measured: From study treatment initiation until within 30 days of the last dose of treatment, up to 6.5 months

  4. Phase 2 - Frequency of Certain Adverse Event (AE)

    Certain Adverse Event (AE) includes frequency of positive surgical margins, extracapsular extension, seminal vesicle invasion and lymph node positivity.

    Measured: 28 days, up to 6 months

  5. Phase 2 - Change in Prostate Specific Antigen (PSA)

    A prostate-specific antigen (PSA) test is a blood test that measures the level of PSA in a sample of blood. PSA test will be done by local institutional labs and reported as nanograms of PSA per milliliter (ng/mL) of blood

    Measured: PSA is measured day 1 of each cycle, up to 6 months. Each cycle is 28 days.

  6. Phase 2 - 3-year Biochemical Progression-free Survival (bPFS) Rate

    3-year bPFS rate is the proportion of participants remaining alive and free of biochemical progression at 3 years. Biochemical progression is defined as a PSA rising to >0.1ng/mL after surgery.

    Measured: At 3 years post radical prostatectomy

  7. Phase 2 - 5-year Progression-free Survival (bPFS) Rate

    5-year bPFS rate is the proportion of participants remaining alive and free of biochemical progression at 5 years. Biochemical progression is defined as a PSA rising to >0.1ng/mL after surgery.

    Measured: At 5 years post radical prostatectomy,

  8. Phase 2 - Proportion Free From Prostate Cancer Therapy

    Proportion free from further prostate cancer therapy will be estimated from the Kaplan Meier methodology by each arm. Further prostate cancer therapy includes salvage radiotherapy and/or ADT.

    Measured: at 2, 3, and 5 years post radical prostatectomy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Nov 2022
  2. Study start9 Aug 2023
  3. Primary completion15 Jul 2025
  4. Study completion1 Jun 2026

Why it stopped: The trial was intended to be Phase 1/2 but did not move forward to Phase 2 since the company providing drug and funding (Lilly) withdrew support for the trial based on data relating to abemaciclib in advanced prostate cancer.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05617885
Sponsor's protocol ID
22-422
Other IDs
P50CA272390
Status last verified
Sep 2026
First submitted
8 Nov 2022
Last updated
15 Oct 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Darolutamide, Abemaciclib and GNRH-A Leuprolide Acetate in people with Metastatic Prostate Cancer and Non-metastatic Prostate Cancer, run by Praful Ravi, MB BCHir, MRCP at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 50 inclusion and 35 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Oct 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Phase 1 - Number of Subjects With Dose Limiting Toxicity (DLT) (time frame: Within the first 28 days of treatment (Cycle 1)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05617885.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in